Armune BioScience, Inc. Announces the Appointment of Robert W. Reinhardt, MD as Chief Medical Officer

Share Article

Dr. Reinhardt will support the launch of the company’s lead product, APIFINY — the only cancer specific, non-PSA blood test available to clinicians for the detection of prostate cancer.

Armune
We are seeing significant growth for our lead product APIFINY and we are grateful to have Dr. Reinhardt join our company at this important stage.

Armune BioScience has announced the appointment of Dr. Robert W. Reinhardt to the position of Chief Medical Officer. An experienced clinician and respected industry executive, Dr. Reinhardt will support the launch of the company’s lead product, APIFINY® — the only cancer specific, non-PSA blood test available to clinicians for the detection of prostate cancer.

In addition to his training as a physician, Dr. Reinhardt is an experienced business executive. He previously served as the Chief Medical Officer of Phadia US Inc., which was purchased by Thermo Fisher Scientific in 2011. After earning his medical degree from Michigan State University (MSU), Dr. Reinhardt spent many years in academic family medicine at Brown University, the University of Michigan, and then at MSU. Currently, he is an Associate Professor of Family Medicine at the Western Michigan University Homer Stryker M.D. School of Medicine.

“I’m excited to be expanding my role with Armune as the company is experiencing strong demand for APIFINY. Clinicians are embracing the potential to move beyond PSA-based testing in the assessment of prostate cancer risk,” said Dr. Reinhardt. “I look forward to increasing our physician education efforts and expanding our clinical development program. The company’s unique technology developed out of research from the University of Michigan has the potential to significantly improve care and reduce the cost of care in many areas of cancer.”

“Dr. Reinhardt’s breadth of experience as a physician and industry executive will add tremendous value to our customers,” said Armune President and CEO David A. Esposito. “We are seeing significant growth for our lead product APIFINY and we are grateful to have Dr. Reinhardt join our company at this important stage.”

Armune BioScience, Inc. develops and commercializes autoantibody technology licensed from the University of Michigan and developed under the direction of Arul Chinnaiyan, MD, PhD. In early 2015, Armune launched APIFINY from the company’s high complexity CLIA laboratory in Ann Arbor, Michigan. Clinicians and patients interested in gaining access to APIFINY should call 844-427-6863 or request information from the company’s website at http://www.armune.com.

Armune continues to raise funds through its current Series A round of investment to support the growth of the business. Interested investors should contact Eli Thomssen, Chief Business Officer, at elthomssen[at]armune.com or by telephone at 269-491-6431.

About Armune BioScience
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. Armune was incorporated as a Delaware Corporation in 2008 with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sue Crookston
@apifiny
since: 04/2015
Follow >
Follow us on
Visit website